SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Aging · 2023
DOI: 10.18632/aging.204913 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2023. Verfasst von Fengxiao An und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological, Melanoma. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China.
- Department of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
- Department of Orthopedics, Sunshine Union Hospital, Weifang 261061, Shandong, China.
- School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Zitieren
APA
An, F., Zhang, W., Guo, Y., Shi, F., Kong, Y., Tang, L., Han, C., & Wang, Q. (2023). SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC. Aging. https://doi.org/10.18632/aging.204913
Vancouver
An F, Zhang W, Guo Y, Shi F, Kong Y, Tang L, et al. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC. Aging. 2023. doi:10.18632/aging.204913
BibTeX
@article{An2023,
author = {An, Fengxiao and Zhang, Wenjing and Guo, Yuxian and Shi, Fuyan and Kong, Yujia and Tang, Liguo and Han, Caijing and Wang, Qinghua},
title = {SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.204913}
}
EUVIMED